Table 2.

Selected data from baseline and study end for 76 patients with type II diabetes mellitus, systolic hypertension, and albuminuria randomized to valsartan and hydrochlorothiazide or amlodipine treatment

VariableValsartan/Hydrochlorothiazide (n=37)Amlodipine (n=39)
Soluble Klotho (pg/ml)
 Baseline432.7±179.0430.1±145.8
 Study end506.4±226.8411.9±157.6
 Change from baseline (95% CI)73.7 (19.2 to 128.2)−18.3 (−29.0 to 65.6)a
 P value0.010.43
Serum phosphate (mg/dl)
 Baseline3.25±1.182.94±0.56
 Study end2.60±0.962.69±1.52
 Change from baseline (95% CI)−0.65 (−0.09 to −1.33)0.22 (−0.03 to 0.90)a
 P value0.040.44
Log FGF-23 (RU/ml)
 Baseline1.21±0.181.31±0.23
 Study end1.32±0.211.29±0.24
 Change from baseline (95% CI)0.11 (0.02 to 0.19)−0.02 (−0.05 to 0.09)
 P value0.010.55
Brachial pulse pressure (mmHg)
 Baseline76.6±11.574.1±9.7
 Study end61.5±13.361.0±10.2
 Change from baseline (95% CI)−15.1 (−12.4 to −17.8)−13.1 (−10.0 to −16.2)
 P value<0.001<0.001
Ao-PWV (m/s)
 Baseline12.4±2.412.2±2.7
 Study end10.7±2.811.8±2.8
 Change from baseline (95% CI)−1.7 (−2.3 to −1.1)−0.5 (−1.3 to 0.04)a
 P value<0.0010.22
  • Data are presented as the mean ± SD unless otherwise stated. 95% CI, 95% confidence interval; FGF-23, fibroblast growth factor 23; Ao-PWV-Aortic-pulse wave velocity, FGF-23-Fibroblast growth factor 23.

  • a P<0.05 between treatment groups.